Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …

Personalized medicine aims to match the right drug with the right patient by using specific
features of the individual patient's tumor. However, current strategies of personalized …

Acute myeloid leukemias (AMLs) are overlapping hematological neoplasms associated with
rapid onset, progressive, and frequently chemo-resistant disease. At diagnosis, classification …

Abstract Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …

Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

Ex vivo drug response profiling is a powerful tool to study genotype–drug response
associations and is being explored as a tool set for precision medicine in cancer. Here we …

Despite improved outcomes achieved in the last decades for children with newly diagnosed
leukaemia and lymphoma, treatment of patients with refractory/relapsed disease remains a …